December 16, 2024 22:07 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
GRAP 4 restrictions reimposed in Delhi as air quality dips to 'severe' category | 39 ministers included in Devendra Fadnavis-led Maharashtra cabinet | People who raise questions on EVMs should show how they can be hacked: TMC trashes Congress claims | Bangladesh likely to hold national polls in late 2025 or early 2026, says Yunus in Victory Day speech | Constitution stood test of time: Nirmala Sitharaman in Rajya Sabha | PM Museum requests Rahul Gandhi to return Pandit Nehru's historical letters | Indian tabla maestro Zakir Hussain dies at 73 in San Francisco, confirms family | Kolkata woman strangled, beheaded and chopped into pieces for refusing brother-in-law's advances | Arvind Kejriwal, CM Atishi to contest Delhi polls from current constituencies | Atul Subhash suicide case: Wife Nikita, her mother and brother arrested

Novartis to cut 680 jobs in product development: Report

| @indiablooms | Apr 10, 2024, at 02:40 am

New Delhi: Swiss pharmaceutical company Novartis said on Tuesday that it plans to reduce its development organization workforce by as many as 680 positions, media reports said.

Nearly 440 of these jobs will be cut in Switzerland and up to 240 in the United States within the next two to three years, reported Reuters.

These reductions are separate from a larger restructuring initiative that may result in up to 8,000 job cuts from Novartis's total global workforce of 78,000, the report said.

In a similar move, Roche, a competitor based in Switzerland, disclosed earlier in the year its decision to eliminate 345 positions from its product development sector.

Currently, Novartis employs around 12,500 individuals in development roles, covering responsibilities such as drug regulation, analytics, and support functions like quality assurance.

These personnel are also engaged in shaping the production processes for drugs following the completion of research activities.

About 3,000 of these positions are situated in Switzerland and 2,000 in the United States, indicating that approximately 14% of roles in these countries will be impacted.

However, Novartis plans to introduce new positions over the coming two to three years, resulting in an overall net reduction of 1-2% globally, the Reuters report said.

The company stated that these changes aim to reconfigure its capabilities to tap into local talent pools, including data scientists and regulatory specialists in Britain.

Despite the workforce adjustments, Novartis affirmed its dedication to development endeavours in both Switzerland and the United States.

According to the Reuters report, a company spokesperson said, "We remain committed to development in Switzerland as our innovation hub for complex development, and providing strategic leadership as the global headquarters for development.

"The US remains a key development hub with strong representation in our global program teams, responsible for advancing our medicines pipeline."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.